Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$7.47 - $10.95 $315,734 - $462,823
42,267 New
42,267 $462,000
Q1 2021

May 11, 2021

SELL
$4.23 - $6.55 $45,620 - $70,641
-10,785 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$5.73 - $9.03 $61,798 - $97,388
10,785 New
10,785 $62,000

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Aigen Investment Management, LP Portfolio

Follow Aigen Investment Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Aigen Investment Management, LP with notifications on news.